280 related articles for article (PubMed ID: 25934076)
1. Targeting Translation Initiation Bypasses Signaling Crosstalk Mechanisms That Maintain High MYC Levels in Colorectal Cancer.
Wiegering A; Uthe FW; Jamieson T; Ruoss Y; Hüttenrauch M; Küspert M; Pfann C; Nixon C; Herold S; Walz S; Taranets L; Germer CT; Rosenwald A; Sansom OJ; Eilers M
Cancer Discov; 2015 Jul; 5(7):768-781. PubMed ID: 25934076
[TBL] [Abstract][Full Text] [Related]
2. Targeting MYC Translation in Colorectal Cancer.
Castell A; Larsson LG
Cancer Discov; 2015 Jul; 5(7):701-3. PubMed ID: 26152922
[TBL] [Abstract][Full Text] [Related]
3. 5'-Cap‒Dependent Translation as a Potent Therapeutic Target for Lethal Human Squamous Cell Carcinoma.
Srivastava RK; Khan J; Arumugam A; Muzaffar S; Guroji P; Gorbatyuk MS; Elmets CA; Slominski AT; Mukhtar MS; Athar M
J Invest Dermatol; 2021 Apr; 141(4):742-753.e10. PubMed ID: 32971126
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation.
Oblinger JL; Burns SS; Huang J; Pan L; Ren Y; Shen R; Kinghorn AD; Welling DB; Chang LS
Exp Neurol; 2018 Jan; 299(Pt B):299-307. PubMed ID: 28610844
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model.
Bordeleau ME; Robert F; Gerard B; Lindqvist L; Chen SM; Wendel HG; Brem B; Greger H; Lowe SW; Porco JA; Pelletier J
J Clin Invest; 2008 Jul; 118(7):2651-60. PubMed ID: 18551192
[TBL] [Abstract][Full Text] [Related]
6. Targeted inhibition of eIF4A suppresses B-cell receptor-induced translation and expression of MYC and MCL1 in chronic lymphocytic leukemia cells.
Wilmore S; Rogers-Broadway KR; Taylor J; Lemm E; Fell R; Stevenson FK; Forconi F; Steele AJ; Coldwell M; Packham G; Yeomans A
Cell Mol Life Sci; 2021 Sep; 78(17-18):6337-6349. PubMed ID: 34398253
[TBL] [Abstract][Full Text] [Related]
7. Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells.
Tögel L; Nightingale R; Chueh AC; Jayachandran A; Tran H; Phesse T; Wu R; Sieber OM; Arango D; Dhillon AS; Dawson MA; Diez-Dacal B; Gahman TC; Filippakopoulos P; Shiau AK; Mariadason JM
Mol Cancer Ther; 2016 Jun; 15(6):1217-26. PubMed ID: 26983878
[TBL] [Abstract][Full Text] [Related]
8. A MYC-GCN2-eIF2α negative feedback loop limits protein synthesis to prevent MYC-dependent apoptosis in colorectal cancer.
Schmidt S; Gay D; Uthe FW; Denk S; Paauwe M; Matthes N; Diefenbacher ME; Bryson S; Warrander FC; Erhard F; Ade CP; Baluapuri A; Walz S; Jackstadt R; Ford C; Vlachogiannis G; Valeri N; Otto C; Schülein-Völk C; Maurus K; Schmitz W; Knight JRP; Wolf E; Strathdee D; Schulze A; Germer CT; Rosenwald A; Sansom OJ; Eilers M; Wiegering A
Nat Cell Biol; 2019 Nov; 21(11):1413-1424. PubMed ID: 31685988
[TBL] [Abstract][Full Text] [Related]
9. Bromodomain and extra-terminal motif (BET) inhibition is synthetic lethal with loss of SMAD4 in colorectal cancer cells via restoring the loss of MYC repression.
Shi C; Yang EJ; Liu Y; Mou PK; Ren G; Shim JS
Oncogene; 2021 Feb; 40(5):937-950. PubMed ID: 33293694
[TBL] [Abstract][Full Text] [Related]
10. Elevated Translation Initiation Factor eIF4E Is an Attractive Therapeutic Target in Multiple Myeloma.
Li S; Fu J; Lu C; Mapara MY; Raza S; Hengst U; Lentzsch S
Mol Cancer Ther; 2016 Apr; 15(4):711-9. PubMed ID: 26939700
[TBL] [Abstract][Full Text] [Related]
11. Deptor Is a Novel Target of Wnt/β-Catenin/c-Myc and Contributes to Colorectal Cancer Cell Growth.
Wang Q; Zhou Y; Rychahou P; Harris JW; Zaytseva YY; Liu J; Wang C; Weiss HL; Liu C; Lee EY; Evers BM
Cancer Res; 2018 Jun; 78(12):3163-3175. PubMed ID: 29666061
[TBL] [Abstract][Full Text] [Related]
12. Metformin blocks MYC protein synthesis in colorectal cancer via mTOR-4EBP-eIF4E and MNK1-eIF4G-eIF4E signaling.
Shen P; Reineke LC; Knutsen E; Chen M; Pichler M; Ling H; Calin GA
Mol Oncol; 2018 Nov; 12(11):1856-1870. PubMed ID: 30221473
[TBL] [Abstract][Full Text] [Related]
13. eIF4E S209 phosphorylation licenses myc- and stress-driven oncogenesis.
Ruan H; Li X; Xu X; Leibowitz BJ; Tong J; Chen L; Ao L; Xing W; Luo J; Yu Y; Schoen RE; Sonenberg N; Lu X; Zhang L; Yu J
Elife; 2020 Nov; 9():. PubMed ID: 33135632
[TBL] [Abstract][Full Text] [Related]
14. Targeting translation initiation by synthetic rocaglates for treating MYC-driven lymphomas.
Zhang X; Bi C; Lu T; Zhang W; Yue T; Wang C; Tian T; Zhang X; Huang Y; Lunning M; Hao X; Brown LE; Devine WG; Vose J; Porco JA; Fu K
Leukemia; 2020 Jan; 34(1):138-150. PubMed ID: 31171817
[TBL] [Abstract][Full Text] [Related]
15. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.
Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S
Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281
[TBL] [Abstract][Full Text] [Related]
16. Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma.
Demosthenous C; Han JJ; Stenson MJ; Maurer MJ; Wellik LE; Link B; Hege K; Dogan A; Sotomayor E; Witzig T; Gupta M
Oncotarget; 2015 Apr; 6(11):9488-501. PubMed ID: 25839159
[TBL] [Abstract][Full Text] [Related]
17. Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies.
Deng C; Lipstein MR; Scotto L; Jirau Serrano XO; Mangone MA; Li S; Vendome J; Hao Y; Xu X; Deng SX; Realubit RB; Tatonetti NP; Karan C; Lentzsch S; Fruman DA; Honig B; Landry DW; O'Connor OA
Blood; 2017 Jan; 129(1):88-99. PubMed ID: 27784673
[TBL] [Abstract][Full Text] [Related]
18. Novel oncogene 5MP1 reprograms c-Myc translation initiation to drive malignant phenotypes in colorectal cancer.
Sato K; Masuda T; Hu Q; Tobo T; Gillaspie S; Niida A; Thornton M; Kuroda Y; Eguchi H; Nakagawa T; Asano K; Mimori K
EBioMedicine; 2019 Jun; 44():387-402. PubMed ID: 31175057
[TBL] [Abstract][Full Text] [Related]
19. Non-immunosuppressive triazole-based small molecule induces anticancer activity against human hormone-refractory prostate cancers: the role in inhibition of PI3K/AKT/mTOR and c-Myc signaling pathways.
Leu WJ; Swain ShP; Chan SH; Hsu JL; Liu SP; Chan ML; Yu CC; Hsu LC; Chou YL; Chang WL; Hou DR; Guh JH
Oncotarget; 2016 Nov; 7(47):76995-77009. PubMed ID: 27769069
[TBL] [Abstract][Full Text] [Related]
20. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies.
Boussemart L; Malka-Mahieu H; Girault I; Allard D; Hemmingsson O; Tomasic G; Thomas M; Basmadjian C; Ribeiro N; Thuaud F; Mateus C; Routier E; Kamsu-Kom N; Agoussi S; Eggermont AM; Désaubry L; Robert C; Vagner S
Nature; 2014 Sep; 513(7516):105-9. PubMed ID: 25079330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
